Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models

BACKGROUND: Despite the poor prognosis of triple-negative breast cancer (TNBC) brain metastases, there are no approved systemic therapies. We explored the DNA-damaging poly(ADP-ribose) polymerase inhibitor (PARPi) niraparib in intracranial mouse models of breast cancer susceptibility protein (BRCA)-...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neurooncol Adv
Asıl Yazarlar: Sambade, Maria J, Van Swearingen, Amanda E D, McClure, Marni B, Deal, Allison M, Santos, Charlene, Sun, Kaiming, Wang, Jing, Mikule, Keith, Anders, Carey K
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Basic and Translational Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212882/
https://ncbi.nlm.nih.gov/pubmed/32642648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz005
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller